Laekna Therapeutics

Executive Summary

Laekna Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, founded in 2016, focused on developing novel small molecule inhibitors for oncology. The company's pipeline primarily targets the PI3K/AKT/mTOR signaling pathway, a key driver of tumor growth and resistance in various solid tumors and hematologic malignancies. Laekna's lead candidates include LAK-2201 (a PI3Kδ inhibitor for hematologic cancers) and LAK-2006 (an AKT inhibitor for solid tumors), both in Phase 2 development. The company aims to address unmet medical needs by overcoming resistance mechanisms to existing therapies, leveraging its expertise in kinase inhibition and precision medicine.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for LAK-2201 in relapsed/refractory B-cell malignancies45% success
• Q4 2026Initiation of Phase 3 trial for LAK-2006 in prostate cancer40% success
• TBDPotential partnership or licensing agreement for PI3Kδ program30% success